Status:
COMPLETED
Hydroxychloroquine Dosing and Toxicity in Ophthalmology Clinics
Lead Sponsor:
The Eye Center and The Eye Foundation for Research in Ophthalmology
Collaborating Sponsors:
King Khalid University Hospital
Conditions:
Hydroxychloroquine Toxic Retinopathy
Eligibility:
All Genders
Brief Summary
This study assesses the ocular toxicity in patients on high dose hydroxychloroquine (HCQ) as per the latest guidelines of the American Academy of Ophthalmology (AAO).
Detailed Description
Hydroxychloroquine (HCQ) is an anti-malarial drug that is used to treat a variety of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, juvenile idiopathic arthritis a...
Eligibility Criteria
Inclusion
- Patients on hydroxychloroquine therapy who came for their ophthalmology screening appointment irrespective of the duration of use of the medication.
Exclusion
- Patients who have stopped their hydroxychloroquine medication.
Key Trial Info
Start Date :
June 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2019
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT04010110
Start Date
June 1 2017
End Date
June 1 2019
Last Update
July 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Eye Center
Riyadh, Saudi Arabia, 11534